Blueprint Medicines Co. (NASDAQ:BPMC) Receives $124.95 Consensus Target Price from Analysts
Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twenty-three analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, fifteen have issued a buy recommendation and one […]
Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twenty-three analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, fifteen have issued a buy recommendation and one […]